

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Mitsutaka Nakamura et al.) Group Art Unit: 1612
Application No.: 14/471,919) Examiner: Snigdha MAEWALL
Filed: August 28, 2014) VIA EFS-WEB
For: AGENT FOR TREATMENT OF)
SCHIZOPHRENIA)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

PRELIMINARY AMENDMENT

Further to the Preliminary Amendment filed August 28, 2014, please amend the
above-identified application as follows:

Amendments to the Claims begin at page 2.

Remarks/Arguments follow the amendment section of this paper.

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-19 (Cancelled)

20. (Currently Amended) A method for treating schizophrenia or manic depressive psychoses in a patient, without causing clinically significant body weight gain in the patient, the method comprising administering to the patient a dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide or a pharmaceutically acceptable salt thereof.

21. (Previously Presented) The method of claim 20, wherein said active compound is (1R,2S,3R,4S)—N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboximide hydrochloride.

22. (Previously Presented) The method of claim 20, wherein 20 mg to 120 mg of said active compound is administered to said patient.

23. (Previously Presented) The method of claim 20, wherein said active compound is administered to said patient orally.

24. (Previously Presented) The method of claim 20, wherein said active compound is administered to said patient without concurrently administering another antipsychotic medication.
25. (Previously Presented) The method of claim 20, wherein said active compound is administered to said patient for a period of at least six weeks.
26. (Previously Presented) The method of claim 20, wherein said patient has a BPRS score of at least 42 and wherein the patient's BPRS score is significantly reduced from a baseline measurement prior to the administering of said active compound.
27. (Previously Presented) The method of claim 20, wherein said active compound is administered once daily.
28. (New) The method of claim 20, wherein the method is for treating manic depressive psychoses.

REMARKS


Claims 20-27 are pending. Claim 20 is amended and claim 28 is added herein. Written description support for the amendments can be found, for example, at page 2, lines 26-30 of the as-filed specification (paragraph [0007] of the published application, U.S. Patent Application Publication No. 2014/0371236). Accordingly, no new matter is added, and entry of the Amendment is respectfully requested.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 5, 2015

By: 
Jennifer R. Gupta
Reg. No. 54,257